Ourania Parra, Weijie Ma, Zhongze Li, Bryan N. Coffing, Konstantinos Linos, Robert E. LeBlanc, Shabnam Momtahen, Aravindhan Sriharan, Jeffrey M. Cloutier, Wendy A. Wells, Shaofeng Yan

PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival

  • Dermatology
  • Histology
  • Pathology and Forensic Medicine
Save to CiteDrive Show PDF

AbstractBackgroundImmunohistochemistry‐based protein biomarkers can provide useful prognostic information in cutaneous melanoma. The independent prognostic value of Ki‐67 has been studied with variable results. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry is a useful new ancillary tool for distinguishing cutaneous nevi from melanoma; however, its prognostic value has not been well studied. We evaluated PRAME as a prognostic marker in cutaneous melanoma, compared to Ki‐67.MethodsWe analyzed the immunohistochemical expression of PRAME and Ki‐67 in 165 melanocytic lesions, including 92 primary melanomas, 19 metastatic melanomas, and 54 melanocytic nevi using tissue microarrays. PRAME immunostaining was scored based on the percentage of positive nuclei: 0 <1%, 1+ 1%–25%, 2+ 26%–50%, 3+ 51%–75%, and 4+ >75%. The percentage of Ki‐67‐positive tumor nuclei was used to calculate the proliferation index.ResultsPRAME and Ki‐67 both showed significantly increased expression in melanomas compared to nevi (p < 0.0001 and p < 0.001, respectively). There was no significant difference in PRAME expression in primary versus metastatic melanomas. By contrast, the Ki‐67 proliferation index was higher in metastatic melanoma than in primary melanoma (p = 0.013). Increased Ki‐67 index correlated with ulceration (p < 0.001), increased Breslow depth (p = 0.001), and higher mitotic rate (p < 0.0001), whereas increased PRAME expression correlated with higher mitotic rate (p = 0.047) and Ki‐67 index (p = 0.007). Increased Ki‐67 index correlated with worse disease‐specific survival in patients with primary melanoma (p < 0.001), but PRAME expression did not show prognostic significance in disease‐specific survival (p = 0.63). In a multivariable analysis of patients with primary melanoma, tumor Breslow depth, ulceration, mitotic rate, and Ki‐67 index were each independent predictors of disease‐specific survival (p = 0.006, 0.02, 0.001, and 0.04, respectively); however, PRAME expression was not predictive of disease‐specific survival (p = 0.64).ConclusionKi‐67 is an independent prognostic marker; although increased PRAME expression correlates with the Ki‐67 proliferation index and mitotic rate, PRAME is not an independent prognostic marker for cutaneous melanoma. PRAME and Ki‐67 are useful ancillary tools for distinguishing benign from malignant melanocytic lesions.

Need a simple solution for managing your BibTeX entries? Explore CiteDrive!

  • Web-based, modern reference management
  • Collaborate and share with fellow researchers
  • Integration with Overleaf
  • Comprehensive BibTeX/BibLaTeX support
  • Save articles and websites directly from your browser
  • Search for new articles from a database of tens of millions of references
Try out CiteDrive

More from our Archive